Aurobac Therapeutics SAS

Quick facts

Phase 2 pipeline

• ATX101 · Cardiovascular
  ATX101 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aurobac Therapeutics SAS portfolio CI brief
• Aurobac Therapeutics SAS pipeline updates RSS